Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences

Author's Avatar
Oct 26, 2022

Alpine+Immune+Sciences%2C+Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have poster presentations for ALPN-303's phase 1 study (RUBY-1) at upcoming scientific conferences.